<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35847514</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2211-3835</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Acta pharmaceutica Sinica. B</Title><ISOAbbreviation>Acta Pharm Sin B</ISOAbbreviation></Journal><ArticleTitle>Enterovirus A71 antivirals: Past, present, and future.</ArticleTitle><Pagination><StartPage>1542</StartPage><EndPage>1566</EndPage><MedlinePgn>1542-1566</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apsb.2021.08.017</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) is a significant human pathogen, especially in children. EV-A71 infection is one of the leading causes of hand, foot, and mouth diseases (HFMD), and can lead to neurological complications such as acute flaccid myelitis (AFM) in severe cases. Although three EV-A71 vaccines are available in China, they are not broadly protective and have reduced efficacy against emerging strains. There is currently no approved antiviral for EV-A71. Significant progress has been made in developing antivirals against EV-A71 by targeting both viral proteins and host factors. However, viral capsid inhibitors and protease inhibitors failed in clinical trials of human rhinovirus infection due to limited efficacy or side effects. This review discusses major discoveries in EV-A71 antiviral development, analyzes the advantages and limitations of each drug target, and highlights the knowledge gaps that need to be addressed to advance the field forward.</AbstractText><CopyrightInformation>© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, the University of Arizona, Tucson, AZ 85721, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, the University of Arizona, Tucson, AZ 85721, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Madeleine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, the University of Arizona, Tucson, AZ 85721, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI147325</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI157046</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008804</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Acta Pharm Sin B</MedlineTA><NlmUniqueID>101600560</NlmUniqueID><ISSNLinking>2211-3835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2C protein</Keyword><Keyword MajorTopicYN="N">Acute flaccid myelitis</Keyword><Keyword MajorTopicYN="N">Antivirals</Keyword><Keyword MajorTopicYN="N">EV-A71</Keyword><Keyword MajorTopicYN="N">Enterovirus A71</Keyword><Keyword MajorTopicYN="N">Foot and mouth disease (HFMD)</Keyword><Keyword MajorTopicYN="N">Hand</Keyword><Keyword MajorTopicYN="N">Picornavirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>18</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35847514</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pii">S2211-3835(21)00307-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tuthill T.J., Groppelli E., Hogle J.M., Rowlands D.J. Picornaviruses. Curr Top Microbiol Immunol. 2010;343:43–89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018333</ArticleId><ArticleId IdType="pubmed">20397067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D., Krogstad P. Enteroviruses in the early 21st century: new manifestations and challenges. Curr Opin Pediatr. 2016;28:107–113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi M.H., Wong S.C., Lewthwaite P., Cardosa M.J., Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyring S.K. Hand foot and mouth disease: enteroviral load and disease severity. EBioMedicine. 2020;62:103115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658477</ArticleId><ArticleId IdType="pubmed">33181466</ArticleId></ArticleIdList></Reference><Reference><Citation>Phyu W.K., Ong K.C., Wong K.T. Modelling person-to-person transmission in an enterovirus A71 orally infected hamster model of hand-foot-and-mouth disease and encephalomyelitis. Emerg Microb Infect. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567166</ArticleId><ArticleId IdType="pubmed">28698666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Liu Y., Liu F., Ren M., Nie T., Cui J., et al. Basic reproduction number of enterovirus 71 coxsackievirus A16 and A6: evidence from outbreaks of hand, foot and mouth disease in China between 2011 and 2018. Clin Infect Dis. 2020;73:e2552–e2559.</Citation><ArticleIdList><ArticleId IdType="pubmed">33320199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C.C., Lau S.K., Lo J.Y., Chan K.H., Woo P.C., Yuen K.Y. Genetic characterization of EV71 isolates from 2004 to 2010 reveals predominance and persistent circulation of the newly proposed genotype D and recent emergence of a distinct lineage of subgenotype C2 in Hong Kong. Virol J. 2013;10:222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3716818</ArticleId><ArticleId IdType="pubmed">23822185</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J., Yan H., Cheng N., Lu X., Hu X., Liang L., et al. The clinical and epidemiological study of children with hand, foot, and mouth disease in Hunan, China from 2013 to 2017. Sci Rep. 2019;9:11662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6690890</ArticleId><ArticleId IdType="pubmed">31406192</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Wanlapakorn N., Vongpunsawad S., Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci. 2019;26:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C., Li Y., Zhou Y., Liang L., Turtle L., Wang F., et al. Enterovirus genomic load and disease severity among children hospitalised with hand, foot and mouth disease. EBioMedicine. 2020;62:103078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7653080</ArticleId><ArticleId IdType="pubmed">33161231</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Lin H.Y., Gau S.S., Lu C.Y., Hsia S.H., Huang Y.C., et al. Enterovirus A71 neurologic complications and long-term sequelae. J Biomed Sci. 2019;26:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688366</ArticleId><ArticleId IdType="pubmed">31395054</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Spence-Davizon E., Osborne C., Press C., Schreiner T.L., Martin J., et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect Dis. 2020;20:230–239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11284833</ArticleId><ArticleId IdType="pubmed">31859216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.C., Badmanathan M., Devi S., Leong K.L., Cardosa M.J., Wong K.T. Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol. 2008;67:532–542.</Citation><ArticleIdList><ArticleId IdType="pubmed">18520772</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh S., Rawlinson W.D., Andrews P.I., Stelzer-Braid S. Global epidemiology of nonpolio enteroviruses causing severe neurological complications: a systematic review and meta-analysis. Rev Med Virol. 2020;30</Citation><ArticleIdList><ArticleId IdType="pubmed">31588651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.C., Wong K.T. Understanding enterovirus 71 neuropathogenesis and its impact on other neurotropic enteroviruses. Brain Pathol. 2015;25:614–624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029433</ArticleId><ArticleId IdType="pubmed">26276025</ArticleId></ArticleIdList></Reference><Reference><Citation>Long L., Xu L., Xiao Z., Hu S., Luo R., Wang H., et al. Neurological complications and risk factors of cardiopulmonary failure of EV-A71-related hand, foot and mouth disease. Sci Rep. 2016;6:23444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4802311</ArticleId><ArticleId IdType="pubmed">27001010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Nicholls J.M., Liu F., Wang J., Feng Z., Liu D., et al. Pulmonary and central nervous system pathology in fatal cases of hand foot and mouth disease caused by enterovirus A71 infection. Pathology. 2016;48:267–274.</Citation><ArticleIdList><ArticleId IdType="pubmed">27020504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee H.K., Zainol M.I., Sam I.C., Chan Y.F. Recent advances in the understanding of enterovirus A71 infection: a focus on neuropathogenesis. Expert Rev Anti Infect Ther. 2021;19:733–747.</Citation><ArticleIdList><ArticleId IdType="pubmed">33183118</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304–309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.Y., Kung Y.A., Shih S.R. Antivirals and vaccines for enterovirus A71. J Biomed Sci. 2019;26:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829–837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M., Meng F., Wang S., Li J., Zhang Y., Mao Q., et al. 2-Year efficacy, immunogenicity, and safety of Vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215:56–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C.Y., Liu C.C. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines. 2018;17:819–831.</Citation><ArticleIdList><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Bian L., Xu M., Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microb Infect. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H., Yi L., Chen X., Zhou H., Zheng H., Lu J., et al. Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China. J Infect. 2021;82:407–413.</Citation><ArticleIdList><ArticleId IdType="pubmed">33373653</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.A., Huang P.N., Huang Y.C., Yang S.L., Tsao K.C., Chiu C.H., et al. Emergence of genotype C1 Enterovirus A71 and its link with antigenic variation of virus in Taiwan. PLoS Pathog. 2020;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7521691</ArticleId><ArticleId IdType="pubmed">32936838</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu S.T., Kobayashi K., Bi X., Ishizaki A., Tran T.T., Phung T.T.B., et al. Newly emerged enterovirus-A71 C4 sublineage may be more virulent than B5 in the 2015−2016 hand-foot-and-mouth disease outbreak in northern Vietnam. Sci Rep. 2020;10:159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6957505</ArticleId><ArticleId IdType="pubmed">31932599</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.S., Liao C.C., Liou A.T., Chou Y.C., Yu Y.Y., Lin C.Y., et al. Novel naturally occurring mutations of enterovirus 71 associated with disease severity. Front Microbiol. 2020;11:610568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838335</ArticleId><ArticleId IdType="pubmed">33519765</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16:368–381.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Koike S. Cellular receptors for enterovirus A71. J Biomed Sci. 2020;27:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954530</ArticleId><ArticleId IdType="pubmed">31924205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798–801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794–797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Chuang H., Yang K.D. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J. 2009;6:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.L., Chou Y.T., Wu C.N., Ho M.S. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol. 2011;85:11809–11820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Poh C.L., Sam I.C., Chan Y.F. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol. 2013;87:611–620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung M.L., Jia L., Yip C.C.Y., Chan J.F.W., Teng J.L.L., Chan K.H., et al. Human tryptophanyl-tRNA synthetase is an IFN-gamma-inducible entry factor for Enterovirus. J Clin Invest. 2018;128:5163–5177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6205371</ArticleId><ArticleId IdType="pubmed">30153112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Peng W., Ren J., Hu Z., Xu J., Lou Z., et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424–429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K., Ding J., Han J.F., Zhang Y., Wu X.Y., He Y.L., et al. Human enterovirus 71 uncoating captured at atomic resolution. J Virol. 2014;88:3114–3126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957924</ArticleId><ArticleId IdType="pubmed">24352461</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler K.L., Yoder J.L., Carnegie M.S., Ashley R.E., Makhov A.M., Conway J.F., et al. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog. 2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Shen L., Wu J., Zou X., Gu J., Chen J., et al. Enterovirus A71 proteins: structure and function. Front Microbiol. 2018;9:286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5826392</ArticleId><ArticleId IdType="pubmed">29515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Melia C.E., Peddie C.J., de Jong A.W.M., Snijder E.J., Collinson L.M., Koster A.J., et al. Origins of enterovirus replication organelles established by whole-cell electron microscopy. mBio. 2019;10 e00951-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561026</ArticleId><ArticleId IdType="pubmed">31186324</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P., Liu Y., Ma H.C., Paul A.V., Wimmer E. Picornavirus morphogenesis. Microbiol Mol Biol Rev. 2014;78:418–437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4187686</ArticleId><ArticleId IdType="pubmed">25184560</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavappa R., Syed R., Flore O., Icenogle J.P., Filman D.J., Hogle J.M. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci. 1994;3:1651–1669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142606</ArticleId><ArticleId IdType="pubmed">7849583</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S., Fry E., Blakemore W., Abu-Ghazaleh R., Jackson T., King A., et al. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus. J Virol. 1997;71:9743–9752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230284</ArticleId><ArticleId IdType="pubmed">9371640</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffett D.B., Llewellyn A., Singh H., Saxentoff E., Partridge J., Boualam L., et al. Progress toward poliovirus containment implementation—worldwide, 2019–2020. MMWR Morb Mortal Wkly Rep. 2020;69:1330–1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498175</ArticleId><ArticleId IdType="pubmed">32941411</ArticleId></ArticleIdList></Reference><Reference><Citation>Uprety P., Graf E.H. Enterovirus infection and acute flaccid myelitis. Curr Opin Virol. 2020;40:55–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">32711392</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoades R.E., Tabor-Godwin J.M., Tsueng G., Feuer R. Enterovirus infections of the central nervous system. Virology. 2011;411:288–305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060663</ArticleId><ArticleId IdType="pubmed">21251690</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H.I., Shih S.R. Neurotropic enterovirus infections in the central nervous system. Viruses. 2015;7:6051–6066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664993</ArticleId><ArticleId IdType="pubmed">26610549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T., Ishizaka A., Nihei C. Transferrin receptor 1 facilitates poliovirus permeation of mouse brain capillary endothelial cells. J Biol Chem. 2016;291:2829–2836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742747</ArticleId><ArticleId IdType="pubmed">26637351</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R.S., Garber C., Funk K.E., Salimi H., Soung A., Kanmogne M., et al. Neuroinflammation during RNA viral infections. Annu Rev Immunol. 2019;37:73–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6731125</ArticleId><ArticleId IdType="pubmed">31026414</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.S., Yao Y.C., Lin S.C., Lee Y.P., Wang Y.F., Wang J.R., et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol. 2007;81:8996–9003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.H., Ong K.C., Wong K.T. Enterovirus 71 can directly infect the brainstem via cranial nerves and infection can be ameliorated by passive immunization. J Neuropathol Exp Neurol. 2014;73:999–1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">25289894</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A., Ekins S., Schmidtke M., Makarov V. Back to the future: advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Eur J Med Chem. 2019;178:606–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Zhou F., Gu B., Ding C., Feng D., Xie F., et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157:669–679.</Citation><ArticleIdList><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A., Franco D., Tucker S., Hilgenfeld R., Froeyen M., Leyssen P., et al. The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014;58:6990–6992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Hu Y., Zhang J., Musharrafieh R., Wang J. A novel capsid binding inhibitor displays potent antiviral activity against enterovirus D68. ACS Infect Dis. 2019;5:1952–1962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167248</ArticleId><ArticleId IdType="pubmed">31532189</ArticleId></ArticleIdList></Reference><Reference><Citation>Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis. 2002;2:264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho J.Y., Chern J.H., Hsieh C.F., Liu S.T., Liu C.J., Wang Y.S., et al. In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71. J Antimicrob Chemother. 2016;71:1922–1932.</Citation><ArticleIdList><ArticleId IdType="pubmed">27098012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Wang Y., He W., Sun Y., Guo Y., Zhong W., et al. Design, synthesis, and evaluation of novel enterovirus 71 inhibitors as therapeutic drug leads for the treatment of human hand, foot, and mouth disease. J Med Chem. 2020;63:1233–1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">31939669</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Yu J., Hao F., He H., Shi X., Hu J., et al. Discovery of potent EV71 capsid inhibitors for treatment of HFMD. ACS Med Chem Lett. 2017;8:841–846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554915</ArticleId><ArticleId IdType="pubmed">28835799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Ye X., Zhang X.Y., Zhu Z., Zhang X., Xu Z., et al. Coxsackievirus A10 atomic structure facilitating the discovery of a broad-spectrum inhibitor against human enteroviruses. Cell Discov. 2019;5:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331555</ArticleId><ArticleId IdType="pubmed">30652025</ArticleId></ArticleIdList></Reference><Reference><Citation>Smee D.F., Evans W.J., Nicolaou K.C., Tarbet E.B., Day C.W. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antivir Res. 2016;131:61–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100981</ArticleId><ArticleId IdType="pubmed">27063860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Meijer A., Froeyen M., Zhang L., Thibaut H.J., Baggen J., et al. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob Agents Chemother. 2015;59:7782–7785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix C., Laconi S., Angius F., Coluccia A., Silvestri R., Pompei R., et al. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Virol J. 2015;12:106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501209</ArticleId><ArticleId IdType="pubmed">26169596</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gualda B., Sun L., Marti-Mari O., Noppen S., Abdelnabi R., Bator C.M., et al. Scaffold simplification strategy leads to a novel generation of dual human immunodeficiency virus and enterovirus-A71 entry inhibitors. J Med Chem. 2020;63:349–368.</Citation><ArticleIdList><ArticleId IdType="pubmed">31809045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P., Zou G., Bailly B., Xu S., Zeng M., Chen X., et al. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerg Microb Infect. 2014;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemar N., Hauser D.A., Maser P. 100 years of suramin. Antimicrob Agents Chemother. 2020;64:e01168-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7038244</ArticleId><ArticleId IdType="pubmed">31844000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P., Zheng Y., Wang W., Hong L., Delpeyroux F., Arenzana-Seisdedos F., et al. Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A. Sci Rep. 2017;7:42902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317167</ArticleId><ArticleId IdType="pubmed">28218309</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., McLaughlin N.P., Pan J., Goldstein S., Hafenstein S., Shimizu H., et al. The suramin derivative NF449 interacts with the 5-fold vertex of the enterovirus A71 capsid to prevent virus attachment to PSGL-1 and heparan sulfate. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4592248</ArticleId><ArticleId IdType="pubmed">26430888</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T., Jia Q., Wong S.M., Chua K.B. In vitro and in vivo inhibition of the infectivity of human enterovirus 71 by a sulfonated food azo dye, brilliant black BN. J Virol. 2019;93 e00061-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6694806</ArticleId><ArticleId IdType="pubmed">31167919</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Manganaro R., Zonsics B., Strating J., El Kazzi P., Lorenzo Lopez M., et al. Fluoxetine inhibits enterovirus replication by targeting the viral 2C protein in a stereospecific manner. ACS Infect Dis. 2019;5:1609–1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6747591</ArticleId><ArticleId IdType="pubmed">31305993</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Sillau S., Hopkins S.E., Otten C., Wilson-Murphy M., Wong B., et al. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology. 2019;92:e2118–e2126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512883</ArticleId><ArticleId IdType="pubmed">30413631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler K.L. Rationale for the evaluation of fluoxetine in the treatment of enterovirus D68-associated acute flaccid myelitis. JAMA Neurol. 2015;72:493–494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5086417</ArticleId><ArticleId IdType="pubmed">25775436</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Manganaro R., Zonsics B., Hurdiss D.L., Zwaagstra M., Donselaar T., et al. Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C. PLoS Biol. 2020;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673538</ArticleId><ArticleId IdType="pubmed">33156822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R., de Boer S.M., van der Linden L., Bauer L., Lyoo H.R., Mate M.J., et al. Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C. Antimicrob Agents Chemother. 2016;60:2627–2638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4862474</ArticleId><ArticleId IdType="pubmed">26856848</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R., Zhang J., Tuohy P., Kitamura N., Bellampalli S.S., Hu Y., et al. Discovery of quinoline analogues as potent antivirals against enterovirus D68 (EV-D68) J Med Chem. 2019;62:4074–4090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055447</ArticleId><ArticleId IdType="pubmed">30912944</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y., Zuo J., Krogstad P., Jung M.E. Synthesis and structure–activity relationship (SAR) studies of novel pyrazolopyridine derivatives as inhibitors of enterovirus replication. J Med Chem. 2018;61:1688–1703.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346733</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Kitamura N., Musharrafieh R., Wang J. Discovery of potent and broad-spectrum pyrazolopyridine-containing antivirals against enteroviruses D68, A71, and coxsackievirus B3 by targeting the viral 2C protein. J Med Chem. 2021;64:8755–8774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179928</ArticleId><ArticleId IdType="pubmed">34085827</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts R.J., Jones R.W., Delong D.C., Reed S.E., Wallace J., Tyrrell D.A. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981;1:1342–1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">6113314</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller F.D., Monto A.S., DeLong D.C., Exelby A., Bryan E.R., Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother. 1985;27:102–106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC176213</ArticleId><ArticleId IdType="pubmed">2984980</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz B.A., Vance L.M. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995;69:4189–4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Yuan S., Zhang C., Wang Y., Wang Y., He G., et al. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother. 2015;59:2654–2665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating J.R., van der Linden L., Albulescu L., Bigay J., Arita M., Delang L., et al. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep. 2015;10:600–615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011;85:10319–10331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R., Ma C., Zhang J., Hu Y., Diesing J.M., Marty M.T., et al. Validating enterovirus D68-2Apro as an antiviral drug target and the discovery of telaprevir as a potent D68-2Apro inhibitor. J Virol. 2019;93 e02221–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6430540</ArticleId><ArticleId IdType="pubmed">30674624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Lovell S., Tiew K.C., Mandadapu S.R., Alliston K.R., Battaile K.P., et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012;86:11754–11762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486288</ArticleId><ArticleId IdType="pubmed">22915796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Ma C., Szeto T., Hurst B., Tarbet B., Wang J. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture. ACS Infect Dis. 2021;7:586–597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944397</ArticleId><ArticleId IdType="pubmed">33645977</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Yogarajah T., Lee R.C.H., Kaur P., Inoue M., Tan Y.W., et al. Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. Sci Rep. 2020;10:8159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235037</ArticleId><ArticleId IdType="pubmed">32424333</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N., Yang J., Zheng B., Zhang Y., Cao Y., Huan C., et al. The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses. J Virol. 2020;94:e00204–e00220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163137</ArticleId><ArticleId IdType="pubmed">32075935</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li G., Yuan S., Gao Q., Lan K., Altmeyer R., et al. In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob Agents Chemother. 2016;60:5357–5367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997834</ArticleId><ArticleId IdType="pubmed">27353263</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Wang Y., Qing J., Shu B., Cao L., Lou Z., et al. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antivir Res. 2014;112:47–58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25446894</ArticleId></ArticleIdList></Reference><Reference><Citation>Davila-Calderon J., Patwardhan N.N., Chiu L.Y., Sugarman A., Cai Z., Penutmutchu S.R., et al. IRES-targeting small molecule inhibits enterovirus 71 replication via allosteric stabilization of a ternary complex. Nat Commun. 2020;11:4775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508794</ArticleId><ArticleId IdType="pubmed">32963221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunaseelan S., Wong K.Z., Min N., Sun J., Ismail N., Tan Y.J., et al. Prunin suppresses viral IRES activity and is a potential candidate for treating enterovirus A71 infection. Sci Transl Med. 2019;11</Citation><ArticleIdList><ArticleId IdType="pubmed">31666401</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Li S., Du L., Chen S., Gao J., Cai Y., et al. Emetine protects mice from enterovirus infection by inhibiting viral translation. Antivir Res. 2020;173:104650.</Citation><ArticleIdList><ArticleId IdType="pubmed">31734270</ArticleId></ArticleIdList></Reference><Reference><Citation>Albulescu L., Strating J.R., Thibaut H.J., van der Linden L., Shair M.D., Neyts J., et al. Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP. Antivir Res. 2015;117:110–114.</Citation><ArticleIdList><ArticleId IdType="pubmed">25752737</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Dobrikov G., Purstinger G., Galabov A.S. Allosteric regulation of phosphatidylinositol 4-kinase III beta by an antipicornavirus compound MDL-860. ACS Infect Dis. 2017;3:585–594.</Citation><ArticleIdList><ArticleId IdType="pubmed">28605587</ArticleId></ArticleIdList></Reference><Reference><Citation>Torney H.L., Dulworth J.K., Steward D.L. Antiviral activity and mechanism of action of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) Antimicrob Agents Chemother. 1982;22:635–638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC183805</ArticleId><ArticleId IdType="pubmed">7181474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Cao L., Gao H., Wu Y., Wang Y., Fang F., et al. Discovery, optimization, and target identification of novel potent broad-spectrum antiviral inhibitors. J Med Chem. 2019;62:4056–4073.</Citation><ArticleIdList><ArticleId IdType="pubmed">30938999</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Yap M.L., Cardosa J., Kuhn R.J., Rossmann M.G. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci U S A. 2013;110:5463–5467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M.I., Zarif F., Poh C.L. Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci. 2021;28:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L., Wang X., Spyrou J.A.B., Kelly J., Ren J., Grimes J., et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol. 2014;21:282–288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Sun N., Wu H., Guo D., Tien P., Dong C., et al. Identification and structure–activity relationships of diarylhydrazides as novel potent and selective human enterovirus inhibitors. J Med Chem. 2016;59:2139–2150.</Citation><ArticleIdList><ArticleId IdType="pubmed">26885567</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Fuchino H., Kawakami H., Ezaki M., Kawahara N. Characterization of a new antienterovirus D68 compound purified from avocado. ACS Infect Dis. 2020;6:2291–2300.</Citation><ArticleIdList><ArticleId IdType="pubmed">32567833</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Gao Q., Yuan S., Wang L., Altmeyer R., Lan K., et al. Characterization of three small molecule inhibitors of enterovirus 71 identified from screening of a library of natural products. Antivir Res. 2017;143:85–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28412182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Jung Y.K., Kim C., Shin J.S., Scheers E., Lee J.Y., et al. A novel series of highly potent small molecule inhibitors of rhinovirus replication. J Med Chem. 2017;60:5472–5492.</Citation><ArticleIdList><ArticleId IdType="pubmed">28581749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Lee H., Thibaut H.J., Lanko K., Rivero-Buceta E., Bator C., et al. Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. PLoS Pathog. 2019;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590834</ArticleId><ArticleId IdType="pubmed">31071193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.F., Jheng J.R., Lin G.H., Chen Y.L., Ho J.Y., Liu C.J., et al. Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors. Emerg Microb Infect. 2020;9:1194–1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448925</ArticleId><ArticleId IdType="pubmed">32397909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo R.L., Kung S.H., Hsu Y.Y., Liu W.T. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J Gen Virol. 2002;83:1367–1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12029152</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N., Montserret R., Lelogeais V., Schuffenecker I., Lina B., Cortay J.C., et al. Blocking human enterovirus 71 replication by targeting viral 2A protease. J Antimicrob Chemother. 2012;67:2865–2869.</Citation><ArticleIdList><ArticleId IdType="pubmed">22865380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.Y., Huang A.C., Hour M.J., Huang S.H., Kung S.H., Chen C.H., et al. Antiviral potential of a novel compound CW-33 against enterovirus A71 via inhibition of viral 2A protease. Viruses. 2015;7:3155–3171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488731</ArticleId><ArticleId IdType="pubmed">26090728</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q., Yameen M., Liu W., Gao Z., Li Y., Peng X., et al. Conformational plasticity of the 2A proteinase from enterovirus 71. J Virol. 2013;87:7348–7356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700279</ArticleId><ArticleId IdType="pubmed">23616646</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Wang Y., Cao L., Wang P., Qing J., Zheng Q., et al. A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus. Antimicrob Agents Chemother. 2016;60:913–924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750679</ArticleId><ArticleId IdType="pubmed">26596952</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie S., Wang K., Yu W., Lu W., Xu K., Wang J., et al. DIDS blocks a chloride-dependent current that is mediated by the 2B protein of enterovirus 71. Cell Res. 2011;21:1271–1275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193483</ArticleId><ArticleId IdType="pubmed">21747413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieva J.L., Madan V., Carrasco L. Viroporins: structure and biological functions. Nat Rev Microbiol. 2012;10:563–574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097105</ArticleId><ArticleId IdType="pubmed">22751485</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong H., Du N., Yang Y., Song L., Zhang W., Tien P. Enterovirus 71 2B induces cell apoptosis by directly inducing the conformational activation of the proapoptotic protein Bax. J Virol. 2016;90:9862–9877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5068536</ArticleId><ArticleId IdType="pubmed">27558414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.H., Wang K., Zhao K., Hua S.C., Du J. The structure, function, and mechanisms of action of enterovirus non-structural protein 2C. Front Microbiol. 2020;11:615965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767853</ArticleId><ArticleId IdType="pubmed">33381104</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Wang P., Wang G.C., Yang J., Sun X., Wu W., et al. Human enterovirus nonstructural protein 2CATPase functions as both an RNA helicase and ATP-independent RNA chaperone. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517893</ArticleId><ArticleId IdType="pubmed">26218680</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganaro R., Zonsics B., Bauer L., Lorenzo Lopez M., Donselaar T., Zwaagstra M., et al. Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors. Antivir Res. 2020;178:104781.</Citation><ArticleIdList><ArticleId IdType="pubmed">32234539</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R., Kitamura N., Hu Y., Wang J. Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorg Chem. 2020;101:103981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390679</ArticleId><ArticleId IdType="pubmed">32559580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Xu Z., Jin M., Shu T., Chen Y., Feng L., et al. Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: in vitro, in vivo, and combination therapy study. Eur J Med Chem. 2020;202:112310.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Hu Y., Zhang J., Wang J. Pharmacological characterization of the mechanism of action of R523062, a promising antiviral for enterovirus D68. ACS Infect Dis. 2020;6:2260–2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057299</ArticleId><ArticleId IdType="pubmed">32692536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Kye S., Quinn K.K., Cooper P., Damoiseaux R., Krogstad P. Discovery of structurally diverse small-molecule compounds with broad antiviral activity against enteroviruses. Antimicrob Agents Chemother. 2015;60:1615–1626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4775951</ArticleId><ArticleId IdType="pubmed">26711750</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M., Heggermont W., Lanke K., Coutard B., Bergmann M., Monforte A.M., et al. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol. 2008;82:4720–4730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2346740</ArticleId><ArticleId IdType="pubmed">18337578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R., van der Linden L., Thibaut H.J., Lanke K.H., Leyssen P., Coutard B., et al. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother. 2013;57:1952–1956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623316</ArticleId><ArticleId IdType="pubmed">23335743</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89:2518–2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan H., Tian J., Zhang C., Qin B., Cui S. Crystal structure of a soluble fragment of poliovirus 2CATPase. PLoS Pathog. 2018;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166989</ArticleId><ArticleId IdType="pubmed">30231078</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan H., Tian J., Qin B., Wojdyla J.A., Wang B., Zhao Z., et al. Crystal structure of 2C helicase from enterovirus 71. Sci Adv. 2017;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409451</ArticleId><ArticleId IdType="pubmed">28508043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurdiss D.L., El Kazzi P., Bauer L., Papageorgiou N., Ferron F.P., Donselaar T., et al. Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes the hexameric complex. bioRxiv. 2021 doi: 10.1101/2021.04.26.440876. Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.26.440876</ArticleId><ArticleId IdType="pmc">PMC8730599</ArticleId><ArticleId IdType="pubmed">34985963</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang M., Cheng A., Wen X., Ou X., Mao S., et al. Enterovirus replication organelles and inhibitors of their formation. Front Microbiol. 2020;11:1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7468505</ArticleId><ArticleId IdType="pubmed">32973693</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy P.D., Strating J.R., van Kuppeveld F.J. Building viral replication organelles: close encounters of the membrane types. PLoS Pathog. 2016;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5082816</ArticleId><ArticleId IdType="pubmed">27788266</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X., Lei X., Zhang Z., Ma Y., Qi J., Wu C., et al. Enterovirus 3A facilitates viral replication by promoting phosphatidylinositol 4-kinase IIIbeta-ACBD3 interaction. J Virol. 2017;91 e00791-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599760</ArticleId><ArticleId IdType="pubmed">28701404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyoo H., van der Schaar H.M., Dorobantu C.M., Rabouw H.H., Strating J., van Kuppeveld F.J.M. ACBD3 is an essential pan-enterovirus host factor that mediates the interaction between viral 3A protein and cellular protein PI4KB. mBio. 2019;10 e02742-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372799</ArticleId><ArticleId IdType="pubmed">30755512</ArticleId></ArticleIdList></Reference><Reference><Citation>Horova V., Lyoo H., Rozycki B., Chalupska D., Smola M., Humpolickova J., et al. Convergent evolution in the mechanisms of ACBD3 recruitment to picornavirus replication sites. PLoS Pathog. 2019;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6695192</ArticleId><ArticleId IdType="pubmed">31381608</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Takebe Y., Wakita T., Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J Gen Virol. 2010;91:2734–2744.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol. 2009;90:1869–1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M., Thibaut H.J., van der Linden L., Lanke K., Heggermont W., Ireland S., et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009;53:1850–1857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Albulescu L., Bigay J., Biswas B., Weber-Boyvat M., Dorobantu C.M., Delang L., et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antivir Res. 2017;140:37–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">28088354</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden E., Ng T.F.F., Campagnoli R., Nix W.A., Konopka-Anstadt J., Selvarangan R., et al. Antifungal triazole posaconazole targets an early stage of the parechovirus A3 life cycle. Antimicrob Agents Chemother. 2020;64 e02372-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7038243</ArticleId><ArticleId IdType="pubmed">31818821</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Ross-Smith N., Proud C.G., Belsham G.J. Cleavage of translation initiation factor 4AI (eIF4AI) but not eIF4AII by foot-and-mouth disease virus 3C protease: identification of the eIF4AI cleavage site. FEBS Lett. 2001;507:1–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11682048</ArticleId></ArticleIdList></Reference><Reference><Citation>de Breyne S., Bonderoff J.M., Chumakov K.M., Lloyd R.E., Hellen C.U. Cleavage of eukaryotic initiation factor eIF5B by enterovirus 3C proteases. Virology. 2008;378:118–122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2580754</ArticleId><ArticleId IdType="pubmed">18572216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D., Chen S., Cheng A., Wang M. Roles of the picornaviral 3C proteinase in the viral life cycle and host cells. Viruses. 2016;8:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810272</ArticleId><ArticleId IdType="pubmed">26999188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y., Zhao X., Cui Z., Wang M., Wang Y., Li L., et al. Cyanohydrin as an anchoring group for potent and selective inhibitors of enterovirus 71 3C protease. J Med Chem. 2015;58:9414–9420.</Citation><ArticleIdList><ArticleId IdType="pubmed">26571192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Shang C., Yang P., Li L., Zhai Y., Yin Z., et al. 4-Iminooxazolidin-2-one as a bioisostere of the cyanohydrin moiety: inhibitors of enterovirus 71 3C protease. J Med Chem. 2018;61:10333–10339.</Citation><ArticleIdList><ArticleId IdType="pubmed">30365311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Li L., He S., Shang C., Sun Y., Liu N., et al. Application of dually activated michael acceptor to the rational design of reversible covalent inhibitor for enterovirus 71 3C protease. J Med Chem. 2019;62:6146–6162.</Citation><ArticleIdList><ArticleId IdType="pubmed">31184893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G.H., Ye Y., Zhang D., Xu X., Si P., Peng J.L., et al. Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening. Eur J Med Chem. 2016;124:981–991.</Citation><ArticleIdList><ArticleId IdType="pubmed">27776325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47:3907–3916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Fan T., Yao X., Wu Z., Guo L., Lei X., et al. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol. 2011;85:10021–10030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R., Atef A., Becker D., Gottschalk F., Tauber C., Wagner S., et al. Phenylthiomethyl ketone-based fragments show selective and irreversible inhibition of enteroviral 3C proteases. J Med Chem. 2018;61:1218–1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">29328649</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yang B., Zhai Y., Yin Z., Sun Y., Rao Z. Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C. Antimicrob Agents Chemother. 2015;59:2636–2646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394787</ArticleId><ArticleId IdType="pubmed">25691647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Ma C., Szeto T., Hurst B., Tarbet B., Wang J. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses. ACS Infect Dis. 2021;7:586–597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944397</ArticleId><ArticleId IdType="pubmed">33645977</ArticleId></ArticleIdList></Reference><Reference><Citation>Boras B., Jones R.M., Anson B.J., Arenson D., Aschenbrenner L., Bakowski M.A., et al.  Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv. 2020 http://doi:10.1101/2020.09.12.293498 Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.12.293498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cao L., Zhai Y., Yin Z., Sun Y., Shang L. Structure of the enterovirus 71 3C protease in complex with NK-1.8k and indications for the development of antienterovirus protease inhibitor. Antimicrob Agents Chemother. 2017;61 e00298-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5487676</ArticleId><ArticleId IdType="pubmed">28461310</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Kusov Y., Nian Y., Ma Q., Wang J., et al. alpha-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem. 2020;63:4562–4578.</Citation><ArticleIdList><ArticleId IdType="pubmed">32045235</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Wu S., Xiao T., Li Y., Su Z., Wei W., et al. Design, synthesis, and evaluation of a novel macrocyclic anti-EV71 agent. Bioorg Med Chem. 2020;28:115551.</Citation><ArticleIdList><ArticleId IdType="pubmed">32503695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Zheng Q., Wang Y., Pang Z., Liu J., Yin Z., et al. Activity-based protein profiling identifies ATG4B as a key host factor for enterovirus 71 proliferation. J Virol. 2019;93 e01092-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880168</ArticleId><ArticleId IdType="pubmed">31554687</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., George S., Kusov Y., Perbandt M., Anemuller S., Mesters J.R., et al. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol. 2013;87:4339–4351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Ang M.J., Lau Q.Y., Poulsen A., Ng F.M., Then S.W., et al. Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease. Sci Rep. 2016;6:33663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028882</ArticleId><ArticleId IdType="pubmed">27645381</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Yang B., Hao F., Wang P., He H., Huang L., et al. Design, synthesis, and biological evaluation of anti-EV71 agents. Bioorg Med Chem Lett. 2016;26:3346–3350.</Citation><ArticleIdList><ArticleId IdType="pubmed">27234148</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng D., Ma Y., Zhang R., Nie Q., Cui Z., Wang Y., et al. Synthesis and structure–activity relationship of alpha-keto amides as enterovirus 71 3C protease inhibitors. Bioorg Med Chem Lett. 2016;26:1762–1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">26916437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y., Ma Y., Ma F., Nie Q., Ren X., Wang Y., et al. Structure–activity relationship study of peptidomimetic aldehydes as enterovirus 71 3C protease inhibitors. Eur J Med Chem. 2016;124:559–573.</Citation><ArticleIdList><ArticleId IdType="pubmed">27614190</ArticleId></ArticleIdList></Reference><Reference><Citation>Steuten K., Kim H., Widen J.C., Babin B.M., Onguka O., Lovell S., et al. Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19. ACS Infect Dis. 2021;7:1457–1468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901237</ArticleId><ArticleId IdType="pubmed">33570381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura N., Sacco M.D., Ma C., Hu Y., Townsend J.A., Meng X., et al. An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity. J Med Chem. 2022;65:2848–2865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536799</ArticleId><ArticleId IdType="pubmed">33891389</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Chen Y.L., Schul W., Wang Q.Y., Gu F., Duraiswamy J., et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A. 2009;106:20435–20439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787148</ArticleId><ArticleId IdType="pubmed">19918064</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C.L., Yeo H., Ye H.Q., Liu S.Q., Shang B.D., Gong P., et al. Inhibition of enterovirus 71 by adenosine analog NITD008. J Virol. 2014;88:11915–11923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosh D.K., Toti K.S., Hurst B.L., Julander J.G., Jacobson K.A. Structure activity relationship of novel antiviral nucleosides against Enterovirus A71. Bioorg Med Chem Lett. 2020;30:127599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534897</ArticleId><ArticleId IdType="pubmed">33031923</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368:1499–1504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199908</ArticleId><ArticleId IdType="pubmed">32358203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C., Chang H.Y., Lin P.F., Chern J.H., Hsu J.T., Chang C.Y., et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009;53:2740–2747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung H.C., Chen T.C., Fang M.Y., Yen K.J., Shih S.R., Hsu J.T., et al. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J Antimicrob Chemother. 2010;65:676–683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110181</ArticleId><ArticleId IdType="pubmed">20089540</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L., Vives-Adrian L., Selisko B., Ferrer-Orta C., Liu X., Lanke K., et al. The RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus family. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4370873</ArticleId><ArticleId IdType="pubmed">25799064</ArticleId></ArticleIdList></Reference><Reference><Citation>Velu A.B., Chen G.W., Hsieh P.T., Horng J.T., Hsu J.T., Hsieh H.P., et al. BPR-3P0128 inhibits RNA-dependent RNA polymerase elongation and VPg uridylylation activities of Enterovirus 71. Antivir Res. 2014;112:18–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25448086</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates M.K., Seley-Radtke K.L. The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: complex modifications to the nucleoside scaffold. Antivir Res. 2019;162:5–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349489</ArticleId><ArticleId IdType="pubmed">30529089</ArticleId></ArticleIdList></Reference><Reference><Citation>Seley-Radtke K.L., Yates M.K. The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold. Antivir Res. 2018;154:66–86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396324</ArticleId><ArticleId IdType="pubmed">29649496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai M.C., Chen H.H., Xu P., Wang R.Y.L. Translation control of Enterovirus A71 gene expression. J Biomed Sci. 2020;27:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6947814</ArticleId><ArticleId IdType="pubmed">31910851</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Bi J., Li F., Wang S., Huang X., Meng X., et al. Antiviral efficacy of flavonoids against enterovirus 71 infection in vitro and in newborn mice. Viruses. 2019;11:625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6669683</ArticleId><ArticleId IdType="pubmed">31284698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou H.Y., Lu W.W., Wu K.Y., Lin C.W., Kung S.H. Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. J Gen Virol. 2016;97:1122–1133.</Citation><ArticleIdList><ArticleId IdType="pubmed">26879094</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Q., Zhu Y., Li J., Chen Z., Han G.W., Kufareva I., et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science. 2013;341:1387–1390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819204</ArticleId><ArticleId IdType="pubmed">24030490</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S.R., Stollar V., Li M.L. Host factors in enterovirus 71 replication. J Virol. 2011;85:9658–9666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196451</ArticleId><ArticleId IdType="pubmed">21715481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Z.Q., Ng Q.Y., Ng J.W.Q., Mahendran V., Alonso S. Recent progress and challenges in drug development to fight hand, foot and mouth disease. Expet Opin Drug Discov. 2020;15:359–371.</Citation><ArticleIdList><ArticleId IdType="pubmed">31470744</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure. Microbiol Immunol. 2014;58:239–256.</Citation><ArticleIdList><ArticleId IdType="pubmed">24527995</ArticleId></ArticleIdList></Reference><Reference><Citation>Roulin P.S., Lotzerich M., Torta F., Tanner L.B., van Kuppeveld F.J., Wenk M.R., et al. Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER–Golgi interface. Cell Host Microbe. 2014;16:677–690.</Citation><ArticleIdList><ArticleId IdType="pubmed">25525797</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgett A.W., Poulsen T.B., Wangkanont K., Anderson D.R., Kikuchi C., Shimada K., et al. Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat Chem Biol. 2011;7:639–647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158287</ArticleId><ArticleId IdType="pubmed">21822274</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts B.L., Severance Z.C., Bensen R.C., Le A.T., Kothapalli N.R., Nunez J.I., et al. Transient compound treatment induces a multigenerational reduction of oxysterol-binding protein (OSBP) levels and prophylactic antiviral activity. ACS Chem Biol. 2019;14:276–287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379863</ArticleId><ArticleId IdType="pubmed">30576108</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Das P., Schmolke M., Manicassamy B., Wang Y., Deng X., et al. Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export. J Cell Biol. 2012;196:315–326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275370</ArticleId><ArticleId IdType="pubmed">22312003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H.H., Kunz A., Simon V.A., Palese P., Shaw M.L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A. 2011;108:5777–5782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078400</ArticleId><ArticleId IdType="pubmed">21436031</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung N.N., Lai K.K., Dai J., Kok K.H., Chen H., Chan K.H., et al. Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. J Gen Virol. 2017;98:946–954.</Citation><ArticleIdList><ArticleId IdType="pubmed">28555543</ArticleId></ArticleIdList></Reference><Reference><Citation>Earley D.F., Bailly B., Maggioni A., Kundur A.R., Thomson R.J., Chang C.W., et al. Efficient blocking of enterovirus 71 infection by heparan sulfate analogues acting as decoy receptors. ACS Infect Dis. 2019;5:1708–1717.</Citation><ArticleIdList><ArticleId IdType="pubmed">31307190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H.R., Poh C.L., Fecondo J., Grollo L. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res. 2012;169:22–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Hong W.J., Chu J.J. Inhibition of enterovirus VP4 myristoylation is a potential antiviral strategy for hand, foot and mouth disease. Antivir Res. 2016;133:191–195.</Citation><ArticleIdList><ArticleId IdType="pubmed">27520386</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng T.Y., Chen L.C., Shyu H.W., Chen S.H., Wang J.R., Yu C.K., et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antivir Res. 2005;67:31–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15916817</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Chu H., Huang J., Zhao X., Ye Z.W., Lai P.M., et al. Viruses harness YxxO motif to interact with host AP2M1 for replication: a vulnerable broad-spectrum antiviral target. Sci Adv. 2020;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455044</ArticleId><ArticleId IdType="pubmed">32923629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T., Li Y., Fan S., Li W., Wang S., Li S., et al. Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent. Eur J Med Chem. 2019;175:172–186.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Zhao B., Chen X., Song N., Wu J., Li G., et al. GS-9620 inhibits enterovirus 71 replication mainly through the NF-kappaB and PI3K–AKT signaling pathways. Antivir Res. 2018;153:39–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">29425831</ArticleId></ArticleIdList></Reference><Reference><Citation>Frausto S.D., Lee E., Tang H. Cyclophilins as modulators of viral replication. Viruses. 2013;5:1684–1701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3738956</ArticleId><ArticleId IdType="pubmed">23852270</ArticleId></ArticleIdList></Reference><Reference><Citation>Peel M., Scribner A. Cyclophilin inhibitors as antiviral agents. Bioorg Med Chem Lett. 2013;23:4485–4492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125669</ArticleId><ArticleId IdType="pubmed">23849880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Mei Q., Li J., He H. Cyclophilin A and viral infections. Biochem Biophys Res Commun. 2012;424:647–650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092870</ArticleId><ArticleId IdType="pubmed">22814107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienkowska-Haba M., Patel H.D., Sapp M. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog. 2009;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709439</ArticleId><ArticleId IdType="pubmed">19629175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Li F., Musharrafieh R.G., Wang J. Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance. Antivir Res. 2016;133:62–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026937</ArticleId><ArticleId IdType="pubmed">27478032</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J., Wang Y., Sun Y., Huang J., Yan W., Wang J., et al. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog. 2014;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W., Qing J., Mei H., Nong J., Huang J., Zhu J., et al. Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition. Bioorg Med Chem Lett. 2015;25:5682–5686.</Citation><ArticleIdList><ArticleId IdType="pubmed">26564266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng S., Meng X., Huang Q., Lei N., Zeng L., Jiang X., et al. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo. Int J Antimicrob Agents. 2019;53:362–369.</Citation><ArticleIdList><ArticleId IdType="pubmed">30599241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Yam W.K., Sun J., Chu J.J.H. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antivir Res. 2018;149:143–149.</Citation><ArticleIdList><ArticleId IdType="pubmed">29175128</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Xiu J., Liu J., Zhang L., Li X., Xu Y., et al. Chebulagic acid, a hydrolyzable tannin, exhibited antiviral activity in vitro and in vivo against human enterovirus 71. Int J Mol Sci. 2013;14:9618–9627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676802</ArticleId><ArticleId IdType="pubmed">23644889</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Xia S., Wang X., Lan Q., Li P., Xu W., et al. Sodium copper chlorophyllin is highly effective against enterovirus (EV) A71 infection by blocking its entry into the host cell. ACS Infect Dis. 2020;6:882–890.</Citation><ArticleIdList><ArticleId IdType="pubmed">32233455</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Yao F., Xue G., Xu Y., Niu J., Cui M., et al. Antiviral effects of simeprevir on multiple viruses. Antivir Res. 2019;172:104607.</Citation><ArticleIdList><ArticleId IdType="pubmed">31563599</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Zhang L., Fan X., Qin C., Liu J. Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo. Bioorg Med Chem Lett. 2012;22:2209–2211.</Citation><ArticleIdList><ArticleId IdType="pubmed">22342145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Xiu J., Zhang L., Qin C., Liu J. Antiviral activity of punicalagin toward human enterovirus 71 in vitro and in vivo. Phytomedicine. 2012;20:67–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">23146421</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Yang Y., Xu Y., Ma C., Qin C., Zhang L. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J. 2011;8:483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212826</ArticleId><ArticleId IdType="pubmed">22029605</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Xiu J., Zhang X., Zhang L., Yan K., Qin C., et al. Antiviral effect of matrine against human enterovirus 71. Molecules. 2012;17:10370–10376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6268984</ArticleId><ArticleId IdType="pubmed">22932217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo T., Yang Y., Yu L., Pan X., Li Y. Lycorine derivative LY-55 inhibits EV71 and CVA16 replication through downregulating autophagy. Front Cell Infect Microbiol. 2019;9:277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692562</ArticleId><ArticleId IdType="pubmed">31448243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou Y.L., Lin Y.W., Chang H.W., Lin H.Y., Shao H.Y., Yu S.L., et al. Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy. PLoS One. 2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3788750</ArticleId><ArticleId IdType="pubmed">24098578</ArticleId></ArticleIdList></Reference><Reference><Citation>Too I.H.K., Bonne I., Tan E.L., Chu J.J.H., Alonso S. Prohibitin plays a critical role in Enterovirus 71 neuropathogenesis. PLoS Pathog. 2018;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5764453</ArticleId><ArticleId IdType="pubmed">29324904</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y., Lin L., Chen Y., Wu S., Si X., Wu H., et al. Curcumin inhibits the replication of enterovirus 71 in vitro. Acta Pharm Sin B. 2014;4:284–294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629085</ArticleId><ArticleId IdType="pubmed">26579397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Yang R., Yuan B., Liu Y., Liu C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B. 2015;5:310–315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629407</ArticleId><ArticleId IdType="pubmed">26579460</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang B., Deng C., Ye H., Xu W., Yuan Z., Shi P.Y., et al. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antivir Res. 2013;97:198–205.</Citation><ArticleIdList><ArticleId IdType="pubmed">23267829</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L.L., Shan C., Deng C.L., Li X.D., Shang B.D., Ye H.Q., et al. Development of a stable Gaussia luciferase enterovirus 71 reporter virus. J Virol Methods. 2015;219:62–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25843263</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine E.A., Osorio J.E. In vivo imaging with bioluminescent enterovirus 71 allows for real-time visualization of tissue tropism and viral spread. J Virol. 2017;91</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5309956</ArticleId><ArticleId IdType="pubmed">27974562</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond C.G., Bolock A.M., Ma C., Luke C.J., Good M., Coyne C.B. Enteroviruses infect human enteroids and induce antiviral signaling in a cell lineage-specific manner. Proc Natl Acad Sci U S A. 2017;114:1672–1677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320971</ArticleId><ArticleId IdType="pubmed">28137842</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang J.O.-L., Zhou J., Zhao X., Li C., Zou Z., Yin F., et al. Development of three-dimensional human intestinal organoids as a physiologically relevant model for characterizing the viral replication kinetics and antiviral susceptibility of enteroviruses. Biomedicines. 2021;9:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831294</ArticleId><ArticleId IdType="pubmed">33477611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Li C., Liu X., Chiu M.C., Wang D., Wei Y., et al. Human intestinal organoids recapitulate enteric infections of enterovirus and coronavirus. Stem Cell Reports. 2021;16:493–504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940440</ArticleId><ArticleId IdType="pubmed">33626333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Herrington D.T., Coats T.L., Kim K., Cooper E.C., Villano S.A., et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36:1523–1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarche M.J., Borawski J., Bose A., Capacci-Daniel C., Colvin R., Dennehy M., et al. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob Agents Chemother. 2012;56:5149–5156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457382</ArticleId><ArticleId IdType="pubmed">22825118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung H.C., Wang H.C., Shih S.R., Teng I.F., Tseng C.P., Hsu J.T. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis. 2011;203:1784–1790.</Citation><ArticleIdList><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan P., Pannecouque C., De Clercq E., Liu X. Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem. 2016;59:2849–2878.</Citation><ArticleIdList><ArticleId IdType="pubmed">26509831</ArticleId></ArticleIdList></Reference><Reference><Citation>Diep J., Ooi Y.S., Wilkinson A.W., Peters C.E., Foy E., Johnson J.R., et al. Enterovirus pathogenesis requires the host methyltransferase SETD3. Nat Microbiol. 2019;4:2523–2537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6879830</ArticleId><ArticleId IdType="pubmed">31527793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>